drug interaction was noted at the time of the interview in only three patients but as they were seen on only one occasion many more may have had varying blood pressure levels.
drug interaction was noted at the time of the interview in only three patients but as they were seen on only one occasion many more may have had varying blood pressure levels.
These studies show that in patients in the community on long-term anticoagulant or antihypertensive drugs particular care is required when additional drug therapy is prescribed and when the patient is advised about self-medication. A record of current drug therapy must be maintained and be available to allow the rational prescription of additional drugs and the review ofall drug therapy at each patient-doctor contact. Further studies of other well-recognized drug interactions are required in the community to indicate the relevance and clinical importance to doctors who prescribe drugs of the formidable lists of substances which interact, such as the 410 pages of tables recently compiled by Martin (1971) . Possibly the inappropriate prescription of fixed doses of a drug to patients in whom wide differences in the absorption, distribution, metabolism, and excretion of the drug may occur may be as important, if not more so, than drug interactions.
Introduction
Platelet and fibrin deposits are found in the renal glomeruli of patients with rapidly progressive glomerulonephritis, malignant hypertension, and transplant rejection when such patients have oliguria. Persistence of fibrin may account in part for reduction of glomerular filtration. In the case of glomerulonephritis circulating immune complexes, when concentrated in the renal filters, damage platelets (Cochrane and Dixon, 1968) so that intraglomerular coagulation follows. The natural renal protective mechanisms are its endothelial cell fibrinolytic potential (Holemans et al., 1965; Holemans et al., 1967) , resulting in the production of small fibrin degradation products which themselves protect platelets from aggregation (Larrieu et al., 1967) and immune damage (Salmon and Lambert, 1971) , and the phagocytic capacity for fibrin and immune complexes of the mesangial and endothelial cells (Vassalli and McCluskey, 1965 (Porter, 1967; Burrows et al., 1970) . In malignant hypertension it is likely that the high intravascular tension, leading to fibrin insudation through arteriolar walls, also damages endothelial cells (Wardle, 1971) , which even in arteries do have some fibrinolytic activity (Onoyama and Tanaka, 1969) . Platelet adhesion may follow, possibly because of exposure to subendothelial collagen and acid mucopolysaccharides (Murase et al., 1971) . Indeed, the proliferative response that is seen in the glomeruli in malignant hypertension is probably due exclusively to fibrin deposition (Ben-Ishay, 1967) . Kincaid-Smith et al. (1968) reported that heparin given as part of a regimen that included corticosteroids and immunosuppressive drugs greatly improved the urine output of six cases of "irreversible" acute renal failure due to glomerulonephritis. Such a measure is a logical extension of the use of heparin in experimental nephritis to prevent glomerular sclerosis (Silfverskiold, 1940; Kleinerman, 1954) . Other groups have likewise reported the favourable effects of heparin on the course of glomerulonephritis (Shires et al., 1966; Conte et al., 1970; Cade et al., 1971) and transplant rejection (McMillan, 1968; MacDonald et al., 1970) . The bad prognosis of anuric glomerulonephritis is well known (Merrill, 1957) . Heparin has great potential in theory because it is not only the only effective antithrombin but it has also anti-inflammatory and anticomplementary actions (Ecker and Gross, 1929) . Caution in the interpretation of results is necessary because heparin has a diuretic action (Majoor et al., 1960) due to antagonism of the renin-angiotensin-aldosterone system (Schlatmann et al., 1964) . Moreover, control of heparin therapy can present special difficulties in the uraemic patient (Pitney et al., 1970) , in whom there is not only hypercoagulability and heparin resistance but also a metabolic platelet defect.
We (Donato et al., 1967) . The activity of the plasma sample taken at 15 minutes was used to calculate the plasma volume. Thereafter plasma samples were collected six-hourly for 48 hours and then twice daily for up to 10 days. Sodium iodide solution was given by mouth twice daily for three weeks in order to ensure thyroid blockade and urinary excretion of the isotopic iodide. In each plasma sample the activities of the separated fibrinogen (125I) and of the free radioiodide (131I and 125j) were counted. Plasma fibrinogen was also measured in each sample by the method of Ratnoff and Menzie (1951) .
Urine collections were made quantitatively for each 24 hours and used for isotope counting, as well as for estimation of endogenous creatinine clearance and urinary sodium and potassium excretion. The body weight, plasma fibrinogen, and plasma volume being known, the intravascular fibrinogen pool could first be calculated. The fractional catabolic rate (F.C.R.) of the labelled fibrinogen, which is the percentage of the intravascular fibrinogen pool that is broken down each day, was calculated in three ways. Firstly, the plasma decay curve was resolved into its two exponential components according to the method of Matthews (1957) . In so doing the percentage of the labelled fibrinogen that remained in the intravascular compartment was also obtained. Secondly, the amount of isotope excreted in the urine for each successive 24-hour period was divided by the mean 24-hour plasma activity for the day as described by Pearson et al. (1958) . The third technique, based on the use of free "3"1-iodide injected together with the 125I-fibrinogen, was also applied in order to correct for the diminished excretion of iodide in patients with impaired glomerular filtration (Donato et al., 1967) . Determination oftheglomerularfiltrationrate by the single-shot 5"Cr-edetic acid clearance method (Chantler et al., 1969) was performed on the third day of the fibrinogen study and again on the eighth day during the period of heparinization. Heparin was infused intravenously from the fifth day of the fibrinogen catabolism study, 10,000 units being given intravenously as the priming dose and at least 20,000 units/500 ml saline/12 hr as the maintenance dose. Heparin treatment was continued for at least four days. Clotting times were monitored with the Dale and Laidlaw coagulometer (Sharnoff and De Blasio, 1970) 
Results
The plan of the study and the response of Case 13 to heparin are shown in Fig. 1, and Among the patients with glomerulonephritis (Cases 6-12) three had increased fibrinogen catabolism, although all three had also some degree of hypertension. In none of the glomerulonephritis patients was there any response of the fibrinogen catabolic rate to heparinization in spite of the fact that subsequent assay showed them to have mean plasma heparin levels in the range 0-05-0-15 mg/ml. As for the transplant patients, two (Cases 13 and 14) of the three who were heparinized showed amelioration of fibrinogen catabolism in response to the heparin (see Fig. 1 ). It is to be noted also that these transplant patients showed increased fibrinogen catabolic rates.
Reference to the 5aCr-edetic acid glomerular filtration rate data, which are given in Fig. 2 , shows, firstly, that the groups were not equally matched, because initially low filtration rates below 20 ml/min were present in two-thirds of the 15 patients in the heparinized group, whereas only five of the 12 patients who were not heparinized had low filtration rates. The seemingly better prognosis of the non-heparinized group must be borne in mind in relation to the results obtained. Since the error of duplicate estimations of aiCr-edetic acid clearance was found to be 7 0%, an increase in glomerular filtration rate of over 10% has been regarded as significant. The number of patients with an increase in glomerular filtration rate by this criterion in each group is shown in Table I . The numbers do not attain statistical significance, but by combination of the more favourable responses in the hypertension and transplant groups, using Kimball's (1954) partition, X2a = 3*4 (for 1 D.F. P < 0-1), which is significant.
The results obtained when increases in glomerular filtration rate were expressed as absolute values are shown in Table II The mean percentage differences in the values studied are summarzed in Table III . The favourable increase in 1" Credetic acid clearance in the heparinized group is apparent, but at first sight the less impressive change in endogenous creatinine clearance is disappointing. It should be remembered, however, that 5iCr-edetic acid clearance has been shown to give a better estimate of the glomerular filtration rate than creatinine clearance in patients suffering from proteinuria and advanced renal failure (Favre and Wing, 1968) and that its reproducibility is better (Chantler et al., 1969) . Glomerular filtration rate determinations from creatinine or inulin clearance can vary by 20%
(Bennett and Porter, 1971 ) but variance in aICr-edetic acid estimations has been estimated at only 4-7% (Francois et al., 1971 ). Nor does 5iCr-edetic acid clearance suffer from errors in urine collection in ill patients. Also of note is the fact that patients on heparin had evidence of slight potassium retention due to aldosterone antagonism, whereas in the standard treatment group there was potassium loss. Serum samples from the patients with glomerulonephritis were used for haemolytic complement assays, and the data are recorded in Fig. 3 in relation to the corresponding plasma heparin levels so as to give an indication of the dose of heparin required for complement inhibition in-vivo. Levels of heparin as high as 15 units/ml resulted in only some 25% inhibition of haemolytic complement, and levels of heparin had to be of the order of 10-15 units/ml to produce any inhibition at all.
Discussion
There have been several reports of the effect of heparinization on the course of patients with renal disease (Kincaid-Smith et al., 1968; Conte et al., 1970; Freedman et al., 1970; Herdman et al., 1970; Cade et al., 1971; Arieff and Pingerra, 1972) but no study so far has taken account of the weak diuretic action of heparin by coincident measurement of glomerular filtration rates. We have attempted to assess the value of heparin critically over a short period of intensive treatment by direct measurement of glomeralar filtration, by studying its effect on radiofibrinogen catabolism, and by estimating its potential for inhibition of complement.
The results show that under conditions of optimal hepariniza-don the "Cr-edetic acid glomerular filtration rate was increased by a mean of 29%. In the group on standard forms oftherapy the mean increase was only 12 1%. Moreover, it has already been emphasized that the latter group started with better filtration rates. It is concluded that optimal heparinization exerts a beneficial effect over and above those of other forms of therapy but, as shown in Tables I-III , with the relatively small groups of patients involved statistical significance was only just achieved. It must also be recognized that the slope technique for analysis of r'Cr-edetic acid clearance is at a disadvantage in patients in renal failure with unknown abnormalities of body water. The action of heparin was to increase the output of sodium while causing reabsorption of potassium. This is consistent with its recorded action as a diuretic with aldosterone antagonism (Majoor et al., 1960; Schlatman et al., 1964) . The minimum effective dose for such action is said to be 30,000 units/day. The characteristic delay in the natriuresis for 24-48 hours was also noted in this study.
It is presumed that heparin increased the glomerular filtration rate by lessening the tendency to glomerular fibrin deposition in accelerated hypertension and progressive glomerulonephritis and after receipt of a renal allograft. There were indeed three patients with accelerated hypertension who also had accelerated fibrinogen catabolism which was ameliorated under the influence of heparin. Administration of heparin in the course of a radiofibrinogen study is the accepted way of demonstrating the presence of intravascular coagulation. Undoubtedly a high intravascular pressure, in causing vascular damage, triggers fibrin deposition, especially in the kidney (Wardle, 1971) . That the primary therapeutic aim is to lower the blood pressure is emphasized by one hypertensive patient (Case 3) whose intravascular coagulation could not be arrested by large doses of heparin but who subsequently responded after bilateral nephrectomy. Heparin resistance in this patient could have been due to the release of large amounts of coagulant platelet factor 4 by the microangiopathic process (Niewiarowski et al., 1968) . A point about heparin that deserves serious consideration is that it may well be used to combat the decline of renal function that is often seen after therapeutic reduction of the blood pressure in accelerated hypertension (Woods and Blythe, 1967) and that at this stage its action as an aldosterone antagonist may be beneficial.
Two of the three transplant patients also showed reduction of their accelerated fibrinogen catabolic rate with heparin, and in Case 13 (Fig. 1 ) the j>:ocess was reversible and quite dramatic. This patient was at the time under treatment for late rejection which clearly involved a vascular process, although no microangiopathic red cell changes were discernible. At the time serum levels of fibrin degradation products were slightly increased. It has been our general experience that fibrinogen catabolic rates are increased, owing in part to intravascular coagulation for up to three weeks after receipt of a renal allograft, but this is the subject of a separate communication.
It is of interest and disappointing to note that none of the five patients with proliferative glomerulonephritis with oliguria, included three with "rapidly progressive glomerulonephritis," showed any response of the increased fibrinogen catabolic rate to heparin. These patients were not, however, receiving any other form of immunosuppression, nor was heparinization pushed to the limit at which bleeding might occur. This result can be contrasted with the recent observations of Arieff and Pingerra (1972) , who produced a good increase in creatinine clearance by the combined use of prednisone, immunosuppressive drugs, and heparin followed by warfarin. They suggested that prednisone acts synergistically with heparin.
In addition, we can now report that the degree of inhibition of haemolytic complement that can be achieved by heparinization is disappointingly small, of the order of 10-20%. The discrepancy between the action of heparin on complement in vitro and in vivo cannot be explained here. Antiheparins in the plasma in chronic renal disease may play some part. Garrotty (1972) , who assessed the effect of heparin on complement with respect to the detection of blood group antibodies, also found that the heparin concentration should be at least 10 units/ml to exert any effect.
In conclusion, it appears that heparin does produce an increase in the glomerular filtration rate in these conditions. During the course of accelerated hypertension a case can be presented for heparinization once the blood pressure has been reduced to safe levels. Heparin also has a beneficial effect in renal transplant rejection with superimposed vascular changes. In glomerulonephritis heparin alone has no dramatic effect but may be useful as an adjunct to immunosuppresisve therapy. Heperinization should be undertaken only when there are facilities for day and night control and only after the blood pressure has been controlled.
